Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Acq. announced
Appointed director
NITROMED INC (NTMD) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/23/2009 8-K Quarterly results
04/09/2009 8-K Form 8-K -- Current report
03/19/2009 8-K Form 8-K -- Current report
02/26/2009 8-K Form 8-K -- Current report
01/28/2009 8-K Form 8-K -- Current report
01/27/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "PRESS RELEASE ISSUED BY NITROMED, INC. ON JANUARY 27, 2009"
01/21/2009 8-K Form 8-K -- Current report
01/15/2009 8-K Form 8-K -- Current report
01/13/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "Press release issued by NitroMed, Inc. on January 12, 2009"
12/31/2008 8-K Form 8-K -- Current report
12/24/2008 8-K Form 8-K -- Current report
12/19/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "PRESS RELEASE ISSUED BY NITROMED, INC. ON DECEMBER 18, 2008"
12/08/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "# # # 3"
11/26/2008 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Voting Agreement, entered into as of November 21, 2008 and effective as of November 17, 2008, by and between NitroMed, Inc., JHP Pharmaceuticals, LLC and certain funds affiliated with Care Capital, LLC"
11/18/2008 8-K Asset disposition, Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, by and among NitroMed, Inc., Newport Acquisition Corp. and Archemix Corp",
"Form of NitroMed Stockholder Agreement and a schedule of signatories thereto",
"Form of Archemix Stockholder Agreement and a schedule of signatories thereto",
"NitroMed and Archemix Announce Merger Agreement",
"Management Presentation Slides"
10/23/2008 8-K Quarterly results
Docs: "Purchase and Sale Agreement, by and between NitroMed, Inc. and JHP Pharmaceuticals, LLC",
"VOTING AGREEMENT This VOTING AGREEMENT is entered into as of October 22, 2008, by and among NitroMed, Inc., a Delaware corporation , and HealthCare Ventures, Rho Ventures and Invus Public Equities, L.P. and JHP Pharmaceuticals, LLC, a Delaware limited liability company . INTRODUCTION A. Concurrently with the execution and delivery of this Agreement, Seller and Buyer are entering into a Purchase and Sale Agreement pursuant to which, among other things, Seller shall sell, convey, assign, transfer and deliver to Buyer, and Buyer shall purchase and acquire from Seller, all of Seller's right, title and interest in and to all of the Acquired Assets, free and clear of any and all Security Interests, and Buyer shall assume from Seller and be responsible for the Assumed Liabilities. Capitalized ter...",
"NitroMed Announces Agreement to Sell BiDil® Drug Business to JHP Pharmaceuticals, LLC —NTMD Reports Financial Results for Third Fiscal Quarter 2008"
09/17/2008 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "NitroMed Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQ's Minimum Bid Price Requirement"
09/10/2008 8-K Entry into a Material Definitive Agreement
08/05/2008 8-K Quarterly results
Docs: "NitroMed Reports Financial Results for Second Fiscal Quarter 2008 - Conference Call and Webcast to be Held Today at 8:00 AM ET -"
06/03/2008 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Assignment of Lease and Assumption Agreement, by and between NitroMed, Inc. and Cubist Pharmaceuticals, Inc",
"Sublease, by and between NitroMed, Inc. and Cubist Pharmaceuticals, Inc"
05/07/2008 8-K Quarterly results
Docs: "NitroMed Reports Financial Results for First Fiscal Quarter 2008 - Conference Call and Webcast Today at 8:00 AM ET-"
03/28/2008 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Other Events, Financi...
Docs: "James G. Ham Resigns from NitroMed — Kenneth M. Bate Appointed Interim Chief Financial Officer — — NitroMed Regains Compliance with NASDAQ Minimum Bid Price Requirement —"
02/29/2008 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "NitroMed Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQ's Minimum Bid Price Requirement"
02/14/2008 8-K Quarterly results
Docs: "NitroMed Reports Financial Results for Fourth Quarter and Full Year 2007 - Conference Call and Webcast Today at 9:00 AM EST- LEXINGTON, MA——NitroMed, Inc. today reported financial results for the fourth quarter and the year ended December 31, 2007. Total revenues for the three months ended December 31, 2007 were $5.0 million compared to $3.5 million for the same period in 2006. BiDil revenues for the fourth quarter were $4.2 million, an increase of $0.7 million, or 21%, over the comparable 2006 period. For the year ended December 31, 2007, the Company reported total revenues of $16.0 million compared to $12.1 million for the same period in 2006, an increase of $3.9 million, or 33%. BiDil accounted for $15.3 million in revenues for the year ended December 31, 2007, representing a $3.2 milli..."
01/17/2008 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Principal Officers; Election of Directors; Appoin...
Docs: "Retention Agreement, between NitroMed, Inc. and Kenneth M. Bate",
"Retention Agreement, between NitroMed, Inc. and James G. Ham, III",
"Retention and Separation Agreement, between NitroMed, Inc. and Jane A. Kramer",
"NitroMed Reports on BiDil XR™ Progress Following FDA Meeting, Announces Restructuring and Suspension of BiDil ® Sales Force, and Retains Investment Bank to Advise on Strategic Options"
10/31/2007 8-K Quarterly results
Docs: "NitroMed Reports Financial Results for Third Quarter 2007 - Conference Call and Webcast Today at 8:30 AM EDT - LEXINGTON, MA——NitroMed, Inc. , an emerging pharmaceutical company and the maker of BiDil , an orally administered medicine approved in the United States for the treatment of heart failure in self-identified black patients, today reported financial results for its third fiscal quarter and year to date ended September 30, 2007. Total revenues for the three months ended September 30, 2007 were $3.8 million compared to $3.4 million for the same period in 2006, an increase of $0.4 million or 10%. For the nine months ended September 30, 2007, total revenues were $11.0 million, compared to $8.6 million for the same period during 2006, an increase of $2.4 million, or 28%. Sales of BiDil ..."
08/01/2007 8-K Quarterly results
Docs: "Press Release issued by NitroMed, Inc. on August 1, 2007"
05/24/2007 8-K Other Events, Financial Statements and Exhibits
Docs: "Placement Agency Agreement, by and between the Company, and Thomas Weisel Partners LLC",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"PRESS RELEASE PRESS RELEASE PRESS RELEASE PRESS RELEASE"
05/22/2007 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ...
Docs: "Transition Agreement, between NitroMed, Inc. and L. Gordon Letts, Ph.D"
05/02/2007 8-K Quarterly results
Docs: "NitroMed Reports Financial Results for First Fiscal Quarter 2007 - Conference Call and Webcast to be Held Today at 4:30 PM ET-"
04/04/2007 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ...
Docs: "Employment Offer Letter, between NitroMed, Inc. and Manuel Worcel, M.D"
03/22/2007 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ...
Docs: "Form of Restricted Stock Agreement entered into between NitroMed, Inc. and certain of its executive officers, together with a schedule of such executive officers"
03/14/2007 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Assignment of Lease and Assumption Agreement, by and between NitroMed, Inc. and Shire Human Genetic Therapies, Inc"
03/08/2007 8-K Quarterly results
Docs: "NitroMed Reports Financial Results for Fourth Quarter and Full Year 2006 - Conference Call and Webcast to be Held Today at 4:30 PM ET- LEXINGTON, MA——NitroMed, Inc. today reported financial results for the fourth quarter and the year ended December 31, 2006. Total revenues for the three months ended December 31, 2006 were $3.5 million compared to $3.7 million for the same period in 2005, a decrease of $0.2 million. BiDil® revenues for the fourth quarter were also $3.5 million, an increase of $0.2 million over the comparable 2005 period. For the year ended December 31, 2006, the Company reported total revenues of $12.1 million compared to $6.0 million for the same period in 2005, an increase of $6.1 million or just over 100%. All revenues for the full year ended December 31, 2006 came from ..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy